Rakesh Sindhi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1689315/publications.pdf

Version: 2024-02-01

76	2,649	236925	189892
papers	citations	25 h-index	50 g-index

82	82	82	2057
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Five Hundred Intestinal and Multivisceral Transplantations at a Single Center. Annals of Surgery, 2009, 250, 567-581.	4.2	343
2	Clinical Intestinal Transplantation: A Decade of Experience at a Single Center. Annals of Surgery, 2001, 234, 404-417.	4.2	334
3	Graft Versus Host Disease in Intestinal Transplantation. American Journal of Transplantation, 2004, 4, 1459-1465.	4.7	137
4	Intestinal Transplantation under Tacrolimus Monotherapy after Perioperative Lymphoid Depletion with Rabbit Anti-Thymocyte Globulin (ThymoglobulinR). American Journal of Transplantation, 2005, 5, 1430-1436.	4.7	112
5	Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transplant International, 2009, 22, 96-109.	1.6	101
6	Host conditioning and rejection monitoring in hepatocyte transplantation in humans. Journal of Hepatology, 2017, 66, 987-1000.	3.7	99
7	STIMULATED RESPONSE OF PERIPHERAL LYMPHOCYTES MAY DISTINGUISH CYCLOSPORINE EFFECT IN RENAL TRANSPLANT RECIPIENTS RECEIVING A CYCLOSPORINE+RAPAMYCIN REGIMEN1. Transplantation, 2000, 69, 432-436.	1.0	94
8	Lymphoproliferative Disorders and De Novo Malignancies in Intestinal and Multivisceral Recipients: Improved Outcomes With New Outlooks. Transplantation, 2009, 88, 926-934.	1.0	93
9	Pediatric small bowel transplantation. Seminars in Pediatric Surgery, 2010, 19, 68-77.	1.1	85
10	SIROLIMUS FOR RESCUE AND PRIMARY IMMUNOSUPPRESSION IN TRANSPLANTED CHILDREN RECEIVING TACROLIMUS1,2. Transplantation, 2001, 72, 851-855.	1.0	81
11	Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities. Surgery, 2013, 153, 150-159.	1.9	71
12	Pharmacokinetics of Sirolimus and Tacrolimus in Pediatric Transplant Patients. American Journal of Transplantation, 2004, 4, 767-773.	4.7	69
13	The Role of ARF6 in Biliary Atresia. PLoS ONE, 2015, 10, e0138381.	2.5	66
14	Replacing calcineurin inhibitors with mTOR inhibitors in children. Pediatric Transplantation, 2005, 9, 391-397.	1.0	52
15	Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus1. Transplantation, 2002, 74, 1721-1724.	1.0	48
16	Pediatric liver transplantation for hepatocellular cancer and rare liver malignancies: US multicenter and singleâ€center experience (1981â€2015). Liver Transplantation, 2017, 23, 1577-1588.	2.4	43
17	Allospecific CD154+ T cells identify rejection-prone recipients after pediatric small-bowel transplantation. Surgery, 2009, 146, 166-173.	1.9	39
18	Longâ€term outcomes and predictors in pediatric liver retransplantation. Pediatric Transplantation, 2015, 19, 866-874.	1.0	36

#	Article	IF	Citations
19	Reduced immunosuppression in pediatric liver-intestine transplant recipients with CD8+CD28â˜' T-suppressor cells. Human Immunology, 2005, 66, 252-257.	2.4	35
20	Genomeâ€wide association studies in biliary atresia. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 267-273.	6.6	35
21	Evolving Trends in Liver Transplant for Metabolic Liver Disease in the United States. Liver Transplantation, 2019, 25, 911-921.	2.4	32
22	Predicting Cellular Rejection With a Cell-Based Assay. Transplantation, 2017, 101, 131-140.	1.0	29
23	Genetic Variants in Major Histocompatibility Complex-Linked Genes Associate With Pediatric Liver Transplant Rejection. Gastroenterology, 2008, 135, 830-839.e10.	1.3	28
24	Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants. Transplantation Proceedings, 2002, 34, 1972-1973.	0.6	27
25	Allospecific CD154â€ƒ+â€ƒTâ€cytotoxic memory cells as potential surrogate for rejection risk in pediatric intestine transplantation. Pediatric Transplantation, 2012, 16, 83-91.	1.0	25
26	Enhanced Donor-Specific Alloreactivity Occurs Independently of Immunosuppression in Children with Early Liver Rejection. American Journal of Transplantation, 2005, 5, 96-102.	4.7	24
27	Allospecific CD154+ T-Cytotoxic Memory Cells Identify Recipients Experiencing Acute Cellular Rejection After Renal Transplantation. Transplantation, 2011, 92, 433-438.	1.0	23
28	Allospecific CD154+ B Cells Associate With Intestine Allograft Rejection in Children. Transplantation, 2010, 90, 1226-1231.	1.0	22
29	Increased Expression of Peripheral Blood Leukocyte Genes Implicate CD14+ Tissue Macrophages in Cellular Intestine Allograft Rejection. American Journal of Pathology, 2011, 179, 1929-1938.	3.8	22
30	Liver Transplantation for Pediatric Liver Cancer. Cancers, 2020, 12, 720.	3.7	22
31	Pediatric Intestinal Transplantation. Gastroenterology Clinics of North America, 2018, 47, 355-368.	2.2	21
32	Technique and outcome of domino liver transplantation from patients with maple syrup urine disease: Expanding the donor pool for live donor liver transplantation. Clinical Transplantation, 2019, 33, e13721.	1.6	21
33	Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma. Scientific Reports, 2016, 6, 38347.	3.3	20
34	Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responsesâ€"potential clinical implications. Journal of Immunological Methods, 2003, 272, 257-272.	1.4	19
35	Elevated Myeloid: Plasmacytoid Dendritic Cell Ratio Associates With Late, but Not Early, Liver Rejection in Children Induced With Rabbit Anti-Human Thymocyte Globulin. Transplantation, 2009, 88, 589-594.	1.0	19
36	Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. Transplantation Proceedings, 2002, 34, 1960.	0.6	18

#	Article	IF	Citations
37	Elevated Myeloid: Plasmacytoid Dendritic Cell Ratio Associates With Early Acute Cellular Rejection in Pediatric Small Bowel Transplantation. Transplantation, 2010, 89, 55-60.	1.0	17
38	Cytokines and Cell Surface Receptors as Target End Points of Immunosuppression with Cyclosporine A. Journal of Interferon and Cytokine Research, 2001, 21, 507-514.	1.2	16
39	Improvements in intestine transplantation. Seminars in Pediatric Surgery, 2018, 27, 267-272.	1.1	15
40	Postâ€transplant lymphoproliferative disorder in pediatric intestinal transplant recipients: A literature review. Pediatric Transplantation, 2018, 22, e13211.	1.0	15
41	Profile of the Pleximmune blood test for transplant rejection risk prediction. Expert Review of Molecular Diagnostics, 2016, 16, 387-393.	3.1	14
42	Persistent donor-specific alloreactivity may portend delayed liver rejection during drug minimization in children. Frontiers in Bioscience - Landmark, 2007, 12, 660.	3.0	14
43	Intestinal Transplantation in Children. Paediatric Drugs, 2011, 13, 149-159.	3.1	13
44	Biliary-Atresia-Associated Mannosidase-1-Alpha-2 Gene Regulates Biliary and Ciliary Morphogenesis and Laterality. Frontiers in Physiology, 2020, 11, 538701.	2.8	13
45	Immune monitoring in small bowel transplantation. Current Opinion in Organ Transplantation, 2010, 15, 349-356.	1.6	12
46	Proliferative Alloresponse of T Cytotoxic Cells Identifies Rejection-Prone Children With Small Bowel Transplantation. Transplantation, 2010, 89, 1371-1377.	1.0	11
47	Pediatric intestinal transplantation. Seminars in Pediatric Surgery, 2017, 26, 241-249.	1.1	11
48	CD154â€expressing CMVâ€specific T cells associate with freedom from DNAemia and may be protective in seronegative recipients after liver or intestine transplantation. Pediatric Transplantation, 2020, 24, e13601.	1.0	11
49	Lymphocyte subset reconstitution in pediatric liver recipients induced with steroidâ€free rabbit antiâ€human thymocyte globulin. Pediatric Transplantation, 2008, 12, 804-808.	1.0	10
50	Liver transplantation for maple syrup urine disease: A global domino effect. Pediatric Transplantation, 2016, 20, 350-351.	1.0	10
51	Lymphocyte subsets may discern treatment effects in children and young adults with post-transplant lymphoproliferative disorder. Pediatric Transplantation, 2003, 7, 370-375.	1.0	8
52	Lymphocyte subset reconstitution patterns in children with small bowel transplantation induced with steroidâ€free rabbit antiâ€human thymocyte globulin. Pediatric Transplantation, 2009, 13, 353-359.	1.0	8
53	Induction regimens and postâ€transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Singleâ€center experience. Pediatric Transplantation, 2020, 24, e13723.	1.0	8
54	Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2006, 69A, 95-103.	1.5	7

#	Article	IF	Citations
55	Proliferative alloresponse of T-cytotoxic cells identifies rejection-prone children with steroid-free liver transplantation. Liver Transplantation, 2009, 15, 978-985.	2.4	7
56	Operational tolerance in intestinal transplantation. American Journal of Transplantation, 2021, 21, 876-882.	4.7	7
57	Long Term Management of Liver Transplant Rejection in Children. BioDrugs, 2000, 14, 31-48.	4.6	6
58	Factors Associated With Neurobehavioral Complications in Pediatric Abdominal Organ Transplant Recipients Identified Using Computable Composite Definitions*. Pediatric Critical Care Medicine, 2020, 21, 804-810.	0.5	5
59	A network-based approach to identify expression modules underlying rejection in pediatric liver transplantation. Cell Reports Medicine, 2022, 3, 100605.	6.5	5
60	Peripheral lymphocyte markers as surrogate measures of immunosuppression and post-transplant clinical states. Clinical and Applied Immunology Reviews, 2004, 4, 225-238.	0.4	3
61	Sirolimus pharmacokinetic differences between children and adults. Pediatric Transplantation, 2006, 10, 872-874.	1.0	3
62	Cellular alloresponses for rejection-risk assessment after pediatric transplantation. Current Opinion in Organ Transplantation, 2011, 16, 515-521.	1.6	3
63	Liver allograft fibrosis and minimization of immunosuppression. Pediatric Transplantation, 2015, 19, 667-668.	1.0	3
64	Autoimmunity, alloimmunity, and chronic liver allograft injury. Pediatric Transplantation, 2012, 16, 402-403.	1.0	2
65	Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens. Scientific Reports, 2015, 5, 15218.	3.3	2
66	Donor mucosal immunocytes perpetuate refractory GVHD after intestinal transplantation without engrafting in recipient bone marrow: Case report and review of the literature. Pediatric Transplantation, 2019, 23, e13350.	1.0	2
67	Liver transplant for inherited metabolic disease among siblings. Clinical Transplantation, 2020, 34, e14090.	1.6	2
68	Multiparametric effect: concentration analyses. Frontiers in Bioscience - Landmark, 2004, 9, 1218.	3.0	1
69	HSV infection and immunosuppression. Liver Transplantation, 2006, 12, 1906-1907.	2.4	1
70	Achieving Ideal Outcome after Intestinal Transplantation. Transplantation, 2017, 101, S34.	1.0	1
71	The Donor Operation: Recovery of Isolated Intestine or Intestine in Continuity with Other Organs. , 2018, , 589-609.		1
72	Longâ€term outcomes of intestinal transplantation from donors aged under 1Âyear. Pediatric Transplantation, 2022, , e14257.	1.0	1

#	Article	IF	Citations
73	Synergistic immunosuppression and unintended consequences. Pediatric Transplantation, 2017, 21, e13047.	1.0	0
74	Functional Assessment of Immunosuppression. , 2008, , 589-598.		0
75	Pediatric Liver Transplantation with Technical Variant Allografts. , 2018, , 169-189.		0
76	Post-Transplant Management. , 0, , 232-241.		0